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Konzentration (MBK) von Polihexanid und Triclosan gegen
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Hintergrund: In einer quantitativen in-vitro Studie wurde der antimikro-
bielleEffektvonPolihexanidundTriclosanunteridentischenVerhältnis-
sengegenReferenzstämmesowieklinischeIsolatevonStaphylococcus
aureus und Escherichia coli bestimmt.
Methoden: Die minimale Hemmkonzentration (MHK) und die minimale
mikrobiozideKonzentration(MMK)wurdengemäßDIN58940-81mittels
Mikro-Verdünnungs-Essay und eines quantitativen Verdünnungstests
gemäß EN 1040 bestimmt. Polihexanid wurde in einer Polyethylene-
Glykol 4000 Lösung, Triclosan in wässriger Lösung angesetzt.
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Research Article OPEN ACCESSErgebnisse: Die MHK von Polihexanid gegen alle getesteten Stämme
lag zwischen 1–2 µg/mL. Die MHK von Triclosan war stammabhängig
und lag bei 0,5 µg/mL für die getesteten Referenzstämme und bei
64 µg/mL für zwei klinischen Isolate. Gegen alle Stämme erreichte
Triclosan bei einer Konzentration von 0,6 µg/mL einen logRF >5 ohne
und logRF >3 mit 0,2% Albuminbelastung. Als Ausnahme erwies sich
S. aureus-Stamm H-5-24, für den eine Triclosan-Konzentration von
0,6 µg/mL bei einer Einwirkungszeit von 1 min ohne bzw. 10 min mit




gegen den bei selber Konzentration eine Einwirkungszeit von 5 min er-
forderlich war.
Schlussfolgerungen: Die klinischen E. coli-Isolate erforderten höhere
MHKs bei Triclosan als die untersuchten Referenzstämme. Für Poli-
hexanid und Triclosan konnte eine stammabhängige Empfindlichkeit
gezeigt werden. Beide Antiseptika werden im klinischen Einsatz jedoch
regelhaftbeiweithöherenKonzentrationeneingesetzt,womitdieunter-
schiedlichen Empfindlichkeiten klinisch keine Rolle spielen sollten.
Schlüsselwörter: Polihexanid, Triclosan, antimikrobiell, minimale
inhibitorischeKonzentration,MHK,minimalemikrobizideKonzentration
Introduction
Due to their different chemical structure, their different
use in clinical practice and their different antimicrobial
capacitythematterofantibioticresistancedoesnotapply
to antiseptics at the moment. So far, for microbicidal
antisepticsnoclinicallyrelevantresistanceisdocumented
[1], [2], [3]. For microbistatic antiseptics, however, the
potential risk for development of resistance can not be
excluded. Examples for microbistatic antiseptics include
benzalkonium chloride [4], Cetylpyridinium chloride [5],
chlorhexidine and triclosan [6], [7]. For hexachlorophene
[1]andchlorhexidine[8]aplasmid-codedresistancewas
shown already.
Furthermore, for some antiseptics and antibiotics, in-
creased resistance against antiseptics was correlated
with increased antibiotic resistance [9], [10]; however,
increased antibiotic resistance has not been associated
with antiseptic resistance so far. Russel et al. [11] could
demonstrate in an in-vitro study that after Pseudomonas
stutzeri was exposed to increasing concentrations of
chlorhexidine after multiple passages, a stable chlor-
hexidineresistancewasachieved.Simultaneouslyresist-
ance against benzalkonium chloride, cetylpyridinium
chloride and triclosan and a number of antibiotics was
increased as well. For Mycobacterium smegmatis our
study group could show a parallel increase in resistance
for isoniazid and triclosan [7].
For the majority of antiseptic compounds the first step
for their antimicrobial action is penetration into the bac-
terial cell. If this penetration is minimized or inhibited,
resistancewillresult.Bacteriaareabletoaltertheircell’s
permeabilitybychangingitslipidcontent,thecomposition
of the outer membrane proteins, plasmid-coded mucous
productionorbyalteringtheaffinityoftheireffluxpumps.
If the efflux pump has an unspecific affinity to several
compounds,resistanceswillresult.Exampleforanefflux
pump with a broad substrate spectrum is AcrAB of
Escherichia coli which is also responsible for the efflux
activity of the membrane-pore-protein TolC, able of
transporting tetracycline, chloramphenicol, fluoroquino-
lones, β-lactams, novobiocin, erythromycin, ethidium
bromide, crystal violet and Acriflavin [12], [13].
Incontrasttoantibioticswhereantibiogrammsaregener-
ated in course of routine clinical microbiological diag-
nosticsforabroadrangeofantibioticsandbacteria,such
routinedataisnotavailableforantisepticsandknowledge
on antimicrobial efficacy is based only on selected, most
often historic, literature. In light of the possibilities for
development of resistance against antiseptics it deems
useful to control the antimicrobial activity of frequently
used antiseptics and possible changes in regular inter-
vals.
Therefore we conducted an in-vitro study investigating
the current antimicrobial efficacy of the frequently used
skin, mucous membrane and wound antiseptics polihex-
anide and triclosan against clinical isolates and defined
laboratory strains of Staphylococcus aureus and E. coli.
Methods
Tested antimicrobial compounds
For polihexanide, we used the commercially available
product Lavasept
® (Fresenius AG, Bad Homburg, Ger-
many) which contains 200 µg/mL polihexanide and
10 µg/mL macrogolum 4000. Because triclosan as pure
substance (Irgasan
®DP 300; CAS No 88032-08-0; Ciba
AG,Basel,Switzerland)isnotsolvableinwater,wediluted
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according to the manufacturer’s recommendation. In a
separate pilot experiment, we could rule out that 9.2%
ethanol itself possesses antimicrobial properties.
Tested clinical isolates and laboratory
strains
Thefollowingbacteriaweretestedusingthemicro-dilution
test: E. coli ATCC 25922; E. coli AG 100 wild type (K-12
argE3 thi-1 rpsL xyl mtl Δ(gal-uvrB) supE44) [14], [15];
E. coli AGT11, containing fabI mutation with resistance
against triclosan; exchange of amino acid in the enoyl-
reductaseinposition93[16];E.coliAGT11K(AcrAB::kan,
deletionoftheE.colieffluxpumpAcrAB)[14];E.coliAGT
11 Kan (AmarCORAB::kan, constructed by replacement
of a chromosomal 1.24-kb BspHI fragment of the mar
locus in AG100 by homologous recombination with the
kanamycin resistance cassette (Kanr) from pKMN33;
deletion of the regulator gene which activate the efflux
pump)[17];S.aureusATCC29213,MRSAstrainsH-5-18,
H-5-19, H-5-20, H-5-24, H-5-26, H-5-27, and H-5-31
(University Clinic Bonn, Germany), MRSA epidemic strain
North-Germany, Niedersachsen and Berlin (Robert Koch
Institute,Wernigerode,Germany);VISAstrainsVe13985,
Ve 1177/98, BK 13230, BK 1704/98, 18 A 026, and
20A063(RobertKochInstitute,Wernigerode,Germany).
Additionally to the micro-dilution test, S. aureus ATCC
29213, MRSA H-5-24, MRSA epidemic strain North-
Germany, E. coli ATCC 25922 and E. coli AGT 11 were
tested in a quantitative suspension test.
Culture media and neutralizing agents
AspolihexanideprecipitatesonMueller-Hintonagar,micro-
organismswereculturedoniso-sensitestbouillon(Oxoid,
Darmstadt, Germany), tryptone soya agar and broth, re-
spectively (Oxoid, Wesel, Germany). As neutralizer for
polihexanide 3% (w/v) Tween 80 (Serva, Heidelberg,
Germany),3%(w/v)saponine(Fluka,Buchs,Switzerland),
0.1 % (w/v) histidine (Serva, Heidelberg, Germany), and
0.1% (w/v) cysteine (Merck, Darmstadt, Germany) was
used. As neutralization of triclosan was not possible with
theusualneutralizationsolution,weusedeggyolk(sterile
egg yolk diluted to 50% by sterile distilled water) in-
stead. However, only triclosan concentrations of 0.6 µg
triclosan/L and less were possible. Therefore, this con-
centration also was the maximum tested concentration
in the quantitative suspension test.
DeterminationoftheMinimumInhibitory
Concentration (MIC)
The MIC was determined following DIN 58940-81 [18]
using a micro-dilution assay. Briefly, using colonies from
a fresh overnight culture an inoculum of 1x10
5 cfu/mL
in the final medium was prepared. 50 µl of the inoculum
were added to 50 µl of the respective antimicrobial test-
dilution and incubated at 36°C ± 1°C for 20h ± 2h.
Determination of the Minimum
Microbicidal Concentration (MMC)
TheMMCwasdeterminedusingthequantitativesuspen-
sion test following Pitten et al. [19] with and without bio-
burden. For each assay, 0.1 ml of the test organism
(10
8–10
9 cfu/mL) in tryptone soya broth was transferred
fromafreshovernightcultureintoatesttube,mixedwith
1 ml distilled sterile water (test without bio-burden) or, in
parallel series, with 1 ml of 0.2% bovine serum albumin
(test without bio-burden), and transferred in 9 ml of the
test solution. At the final time of action (30 sec, 60 sec,
5 min, 10 min, 60 min, respectively) 1 ml of the test
mixture was transferred into 9 ml tryptical-soy-broth with
addition of the respective neutralizer. After 5 minutes of
neutralisation, serial dilutions were plated on trypticase-
soy-agar. Colonies were counted after 48h. The log10
reduction factor (RF) for each application time was cal-
culated using the formula: log10 (control) – log10 (test
sample). All experiments were performed in triplicate.
Bothantisepticsweretestedatconcentrationsof2µg/mL,
0.2 µg/mL and 0.02 µg/mL.
Statistical analysis
Allassayswererepeated6-fold,andnumberoforganisms
were averaged as mean cfu/ml and expressed as log10.
The log10 reduction factor (logRF) was calculated as log10
of the pre-value minus log10 of the post-value.
Results
Microbistatic activity
For S. aureus no difference was observed in the anti-
microbial activity of polihexanide at concentrations of 1
and 2 µg/mL against ATCC reference strains, 10 MRSA
isolates and 6 VISA strains (Table 1). Triclosan could be
tested only against the ATCC strains and the epidemic
North-German MRSA strain. Compared to MRSA strains
theantimicrobialactivityoftriclosanwas512timeslower.
All E. coli ATCC reference strains and the E. coli wild type
AG100wereinhibitedbytriclosanconcentrationsranging
between0.5and1µg/mL.E.coliAGT11withamutation
in its enoylacyl-carrierprotein-reductase and E. coli AGT
Kan11, a strain identical to E. coli AGT 11 but with add-
itionally defect efflux pump regulation showed an in-
creasedMICbythefactor128againsttriclosan.ForE.coli
AGT 11K, again a strain identical to E. coli AGT 11 but
additionallywithswitched-offeffluxpumpAcrABtriclosan
resistance was decreased by 32 times (Table 2). The
minimum microbistatic concentration for polihexanide
was 2 µg/mL against all tested E. coli strains.
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S. aureus and different MRSA and VISA-strains
Table 2: MIC (µg/mL) of polihexanide and triclosan against
E. coli
Microbicidal activity
In the quantitative suspension test polihexanide showed
superior activity than triclosan (Table 3). S. aureus ATCC
strainsdidnotdifferintheirsusceptibilityagainsttriclosan
ascomparedtotheNorth-GermanepidemicMRSAstrain.
The minimum requirements of a logRF >5 without and
logRF >3 with 0.2% albumin burden within 5 minutes
application time [19] were achieved at a concentration
of 0.6 µg/mL triclosan. The exception was MRSA strain
H-5-24, where a triclosan concentration of 0.6 µg/mL
was able only after 60 sec without and 10 minutes with
albumin burden to achieve a logRF >5 or a logRF >3 re-
duction,respectively.ThedifferencebetweenE.coliATCC
25922 und E. coli AGT 11 was only minute, for both
strains a concentration of 0.6 µg/mL triclosan at an ap-
plication time of 60 sec was needed to achieve a logRF
>5 without and a logRF >3 with albumin-burden.
Table3:Timeandconcentrationdependantbactericidalactivity
of polihexanide and triclosan
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with albumin burden at concentrations of 0.6 µg/mL
within 30 sec, respectively, for S. aureus. The only ex-
ception was the North-German epidemic MRSA strain,
were an application time of 5 minutes was required.
MRSA H-5-24 did not differ in its susceptibility from the
ATCC reference strains. E. coli AGT 11 was only lesser
susceptible to polihexanide as compared to E. coli ATCC
25922underthepresenceofanalbuminburden.Without
albumin burden a logRF >5 was achieved with a concen-
tration of 0.2 µg/mL and an application time of 30 sec,
or 0.02 µg/mL and 60 sec, respectively. With albumin
burden even an application time of 1 minute was not
sufficientforaconcentrationof0.02µg/mLpolihexanide
to achieve a logRF >3.
Discussion
In order to assess the efficacy of the tested antimicrobial
compounds polihexanide and triclosan, our results must
take their usual clinically used concentrations into ac-
count. Triclosan usually is used in liquid soap at con-
centration of 2 to 5 µg/mL, in toothpaste starting from
3 µg/mL and in hand disinfectants ranging from 2 to
20 µg/mL [7].
Woundantisepticscontainingpolihexanideastheiractive
ingredient contain concentrations of 0.2 to 1 µg/mL and
sanitizers 1 to 2 µg/mL. Our results showed that the re-
quired minimum concentration for triclosan and polihex-
anideare0.6µg/mL,andtherefore,concentrationsused
in clinical still are far above the MIC demonstrated for
various clinical isolates and laboratory reference strains.
The focus of our study, however, was not to assess the
antimicrobial efficacy in clinical practice, but rather to
explore differences in susceptibility within various anti-
biotic susceptible strains of S. aureus and E. coli in order
to detect possible induction of co-resistance against an-
tiseptics.
The results of our study showed that the susceptibility of
theepidemicNorth-GermanMRSAstrainagainsttriclosan
was reduced as compared to antibiotic susceptible
strains.AlsoMRSAH-5-24showedreducedsusceptibility
againsttriclosan.Asexpected,triclosanwashighlyeffect-
ive against the E. coli ATCC strain. In contrast, clinical
E. coli isolates showed decreased susceptibility against
triclosan. The mode of action of triclosan is based on the
inhibition of the biosynthesis of lipid acid and enoylacyl-
carrierprotein-reductase [7]. For E. coli to become resist-
ant against triclosan, a single change of 1 amino acid in
the reductase enzyme is sufficient resulting in a 32- to
128-fold MIC increase.
Another reason for the increased resistance of E. coli
against triclosan could also be an increased activity of
the efflux pump AcrAB-TolC located in the bacterial cell
membrane. E. coli mutants with increased efflux pump
activity showed higher MIC values against various anti-
bioticsaswellastriclosanthanstrainswithnormalefflux
pump activity. This correlation was also observed earlier
by McMurry et al. [14] and was explained by the fact that
affected compounds are substrates of the same mem-
brane pump AcrAB-TolC. Our observation of a multiple
antibiotic-resistance-phenotype combined with an in-
crease in triclosan MIC by 1 to 2 titres in some clinical
E. coli isolates confirms this possibility.
With one exception MICs of antibiotic resistant and sus-
ceptible strains against polihexanide did not differ
showingthatpolihexanidehasadifferentmodeofaction
against bacteria [20]. Furthermore, the observed low
MICs for polihexanide allow the conclusion that polihex-
anide is not an substrate for above efflux pumps. Based
onthepresentedin-vitroresultsandclinicalobservations
[21], it is explainable why polihexanide is a very effective
woundantiseptic.Ourdatashowthatpolihexanideeasily
is able to kill even antibiotic resistant bacteria commonly
found as the cause of wound infection. Currently, it can
be concluded that unlike triclosan, polihexanide is not
transported outside of the bacterial cell wall by the
activity of efflux pumps, and therefore is not subject to
development of possible bacterial resistance. Moreover,
polihexanide is integrated into the bacterial cell mem-
brane, which it irreversibly destroys.
However, as with all antimicrobial compounds, it seems
prudent to limit its use to clinically justifiable indications.
Conclusion
The clinical isolates of E. coli generally showed higher
MICs against triclosan, both in the micro-dilution assay
as well in the quantitative suspension suspension test
than comparable ATCC laboratory reference strains. For
polihexanideandtriclosanstraindependantsusceptibility
was shown. However, both antimicrobial compounds are
effective when used in concentrations common in prac-
tice.
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